Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 728

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

Open access
Specks, Ulrich, Merkel, Peter A., Seo, Philip, Spiera, Robert, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Fessler, Barri J., Ding, Linna, Viviano, Lisa, Tchao, Nadia K., Phippard, Deborah J., Asare, Adam L., Lim, Noha, Ikle, David, Jepson, Brett, Brunetta, Paul, Allen, Nancy B., Fervenza, Fernando C., Geetha, Duvuru, Keogh, Karina, Kissin, Eugene Y., Monach, Paul A., Peikert, Tobias, Stegeman, Coen, Ytterberg, Steven R., Mueller, Mark, Sejismundo, Lourdes P., Mieras, Kathleen, Stone, John H.·2013·New England Journal of Medicine

Abstract

BACKGROUND: The 18-month efficacy of a single course of rituximab as compared with conventional immunosuppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown. METHODS: In a multicenter, randomized, double-blind, double-dummy, noninferiority trial, we compared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks) followed by placebo with cyclophosphamide administered for 3 to 6 months followed by azathioprine for 12 to 15 months. The primary outcome measure was complete remission of disease by 6 months, with the remission maintained through 18 months. RESULTS: A total of 197 patients were enrolled. As reported previously, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months. At 12 and 18 months, 48% and 39%, respectively, of the patients in the rituximab group had maintained the complete remissions, as compared with 39% and 33%, respectively, in the comparison group. Rituximab met the prespecified criteria for noninferiority (P<0.001, with a noninferiority margin of 20%). There was no significant difference between the groups in any efficacy measure, including the duration of complete remission and the frequency or severity of relapses. Among the 101 patients who had relapsing disease at baseline, rituximab was superior to conventional immunosuppression at 6 months (P=0.01) and at 12 months (P=0.009) but not at 18 months (P=0.06), at which time most patients in the rituximab group had reconstituted B cells. There was no significant between-group difference in adverse events. CONCLUSIONS: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months. (Funded by the National Institute of Allergy and Infectious Diseases and others; RAVE ClinicalTrials.gov number, NCT00104299.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1213277

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 728

Metadata

Authors
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., Viviano, L., Tchao, N. K., Phippard, D. J., Asare, A. L., Lim, N., Ikle, D., Jepson, B., Brunetta, P., Allen, N. B., Fervenza, F. C., Geetha, D., Keogh, K., Kissin, E. Y., Monach, P. A., Peikert, T., Stegeman, C., Ytterberg, S. R., Mueller, M., Sejismundo, L. P., Mieras, K., & Stone, J. H.
Venue
New England Journal of Medicine
Published
2013-08
Volume
369
Issue
5
Pages
417-427
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2171643265
Cited by
728
References
33
FWCI
57.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. https://app.cochat.ai/papers/10.1056/nejmoa1213277
The paper
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., Viviano, L., Tchao, N. K., Phippard, D. J., Asare, A. L., Lim, N., Ikle, D., Jepson, B., Brunetta, P., Allen, N. B., . . . Stone, J. H. (2013). Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1213277

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.